EFFECTIVENESS OF BOTULINUM TOXIN TYPE A IN CARPAL TUNNEL SYNDROME

2016 ◽  
Vol 19 (02) ◽  
pp. 1650006 ◽  
Author(s):  
Francisco J. Juan-García ◽  
Jacobo Formigo-Couceiro ◽  
Manuela Barrio-Alonso ◽  
Rubén Ouviña-Arribas
Keyword(s):  
Botulinum Toxin ◽  
Carpal Tunnel Syndrome ◽  
Carpal Tunnel ◽  
Botulinum Toxin Type A ◽  
Type A ◽  
Botulinum Toxin Type ◽  
Toxin A ◽  
Surgical Methods ◽  
Patient Reported ◽  
Tunnel Syndrome

Background and objectives: Carpal tunnel syndrome (CTS) is caused by compression of the median nerve as it passes through the wrist. It can be treated with both surgical and non-surgical methods. Botulinum toxin type A has been used in the treatment of spasms, dystonia, migraine relief and myofascial pain. This study is aimed at evaluating the safety and tolerability of botulinum toxin type A in carpal tunnel syndrome. Methods: We conducted an open-label, prospective study using 30 units of onabotulinum Toxin A (Botox[Formula: see text]), injected into the carpal tunnel using the in-plane ultrasound-guided ulnar approach. We used the verbal numeric rating scale (VNRS) to assess changes in pain and paraesthesias both 4 and 12 weeks following the injection. All adverse effects were recorded. Results: A total of 18 patients with 22 mild-moderate idiopathic CTS were included in the study. A total of 14 women and 4 men with a mean of age [Formula: see text] years. Botulinum toxin A was well tolerated and only one patient reported temporary subjective weakness in his/her hand muscles. Both at 4 weeks and 3 months following the injection we observed a 63.6% subjective improvement in the patients’ level of pain and paraesthesias, with no statistical significance ([Formula: see text]). Conclusion: Our study shows the effects of botulinum toxin in relieving pain and paraesthesias in carpal tunnel syndrome with moderate symptoms. The use of an in-plane ultrasound approach for its injection into the carpal tunnel adds value and safety to the procedure, and, based on our experience, is well tolerated and safe. Further studies are required to confirm these results and define optimal doses of botulinum toxin.

Efficacy of Botulinum Toxin Type??A??in??the??Relief of Carpal??Tunnel??Syndrome

2006 ◽  
Vol 26 (9) ◽  
pp. 511-515 ◽  
Author(s):  
Ching-Piao Tsai ◽  
Chih-Yang Liu ◽  
Kon-Ping Lin ◽  
Kai-Chen Wang
Keyword(s):  
Botulinum Toxin ◽  
Carpal Tunnel Syndrome ◽  
Carpal Tunnel ◽  
Botulinum Toxin Type A ◽  
Type A ◽  
Botulinum Toxin Type ◽  
Tunnel Syndrome

Evidence-Based Review of Patient-Reported Outcomes With Botulinum Toxin Type A

2004 ◽  
Vol 27 (5) ◽  
pp. 234-244 ◽  
Author(s):  
Joseph Jankovic ◽  
Alberto Esquenazi ◽  
Darcy Fehlings ◽  
Fred Freitag ◽  
Amy M Lang ◽  
...  
Keyword(s):  
Botulinum Toxin ◽  
Patient Reported Outcomes ◽  
Botulinum Toxin Type A ◽  
Type A ◽  
Botulinum Toxin Type ◽  
Evidence Based ◽  
Patient Reported

Modern approaches to the treatment and rehabilitation of patients with facial neuropathy

2020 ◽  
Vol 96 (2) ◽  
pp. 59-67
Author(s):  
L.B. Zavaliy ◽  
S.S. Petrikov ◽  
G.R. Ramazanov ◽  
D.S. Kasatkin ◽  
K.I. Chekhonatskaya
Keyword(s):  
Botulinum Toxin ◽  
Physical Education ◽  
Facial Nerve ◽  
Therapy Group ◽  
Botulinum Toxin Type A ◽  
Type A ◽  
Botulinum Toxin Type ◽  
Clinical Situation ◽  
Social Adaptation ◽  
Surgical Methods

Facial nerve neuropathy can manifest itself with gross organic and functional disorders. The esthetic defect worsens social adaptation and quality of life. However, there is no consensus, protocol or algorithm of treatment of the patient with this pathology. In article we present a modern way of treatment and rehabilitation of patients with neuropathy of a facial nerve of various etiology. Conservative and surgical types of treatment are applied during the different periods of a disease. Surgical methods of treatment can be divided into two groups: reconstructive, decompressive and also plastic. The choice of a type of operation is defined individually with many factors, including an etiology and time of a disease. Both the new and tested by time techniques are applied. Conservative therapy includes corticosteroids, antiviral, antibacterial drugs depending on a clinical situation. Traditionally specialists of policlinics and hospitals appoint additional therapy (group B vitamins, cholinesterase inhibitors, antioxidants, neuroprotectors, nootropic drugs), however single small researches couldn't enforce these drugs recommendations. Botulinum toxin type A is effective in the acute and chronic periods of a disease. Depending on a clinical situation of botulinum toxin type A are injected both in affected, and in healthy part of the face. Patients with incomplete eye closure are given keratoprotection as early as possible, and blepharography is performed in case of pronounced deficit. As an alternative method, botulinum toxin type A injections are used into the upper eyelid lifting muscle. One of the most effective methods of rehabilitation of patients with facial nerve neuropathy is therapeutic physical education such as neuromuscular retraining with biological feedback. The most optimal combination is the injection of botulinum toxin type A and therapeutic physical education.

scholarly journals Contralateral Upper Limb Weakness Following Botulinum Toxin A Injection for Poststroke Spasticity

2020 ◽  
Vol 33 (11) ◽  
pp. 761
Author(s):  
Alexandre Camões- Barbosa ◽  
Inês Mendes Ribeiro ◽  
Luisa Medeiros
Keyword(s):  
Botulinum Toxin ◽  
Upper Limb ◽  
Botulinum Toxin A ◽  
Neuromuscular Block ◽  
Botulinum Toxin Type A ◽  
Type A ◽  
Deltoid Muscle ◽  
Botulinum Toxin Type ◽  
Toxin A ◽  
Limb Weakness

Botulinum toxin type A has been approved for spasticity management in poststroke patients. The adverse effects are generally of two types: those related to local injection; and those related to the systemic effects from spread of the toxin. Contralateral weakness after botulinum toxin A treatment is a rarely reported adverse effect. We report the case of a 33-year-old female who had been receiving regular injections of incobotulinum toxin A due to spasticity of the right limbs after a hemorrhagic stroke. A switch was made to abobotulinum toxin A with an overall conversion ratio of 1:3.83. The patient presented contralateral upper limb paresis, especially of the deltoid muscle, in the second week post-injection. The electroneuromyography showed neuromuscular block due to botulinum toxin A. She recovered completely after eight months. A switch between different formulations of botulinum toxin type A should prompt caution when carrying out unit conversions. Distant side effects may appear, including paresis in the contralateral limbs.

Sign in / Sign up

Export Citation Format

Share Document